What is the most recent earnings date for ENTO stock?
ENTERO THERAPEUTICS INC (ENTO) last reported earnings on 11/11/2025.
NASDAQ:ENTO • US33749P5070
Past quarterly earnings results for ENTERO THERAPEUTICS INC (ENTO), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q2 2025 | - | - | - | - | ||||
| Q1 2025 | - | - | - | - | ||||
| Q4 2024 | -0.42 | - | 97.39% | - | - | |||
| Q3 2024 | -1.77 | -0.98 | -80.76% | 93.59% | - | - | ||
| Q2 2024 | -10.11 | -4.74 | -113.16% | 91.08% | - | - | ||
| Q1 2024 | -1.92 | -7.44 | 74.18% | 98.24% | - | - | ||
| Q4 2023 | -16.05 | -12.35 | -29.99% | 97.18% | - | - | ||
| Q3 2023 | -27.60 | -37.64 | 26.67% | -102.53% | - | - | ||
| Q2 2023 | -113.40 | -63.65 | -78.17% | 96.40% | - | - | ||
| Q1 2023 | -109.20 | -130.36 | 16.23% | 98.69% | - | - | ||
| Q4 2022 | -568.20 | -177.79 | -219.60% | 94.84% | - | - | ||
| Q3 2022 | 1,092.00 | -1,289.48 | 184.69% | 102.65% | - | - | ||
| Q2 2022 | -3,150.00 | -8,161.02 | 61.40% | 84.38% | - | - | ||
| Q1 2022 | -8,316.00 | -6,811.56 | -22.09% | 52.86% | - | - | ||
| Q4 2021 | -11,007.23 | -9,724.72 | -13.19% | 71.82% | - | - | ||
| Q3 2021 | -41,202.00 | -10,281.60 | -300.74% | -92.35% | - | - | ||
| Q2 2021 | -20,160.00 | -9,317.70 | -116.36% | 5.88% | - | - | ||
| Q1 2021 | -17,640.00 | -9,317.70 | -89.32% | 30.00% | - | - | ||
| Q4 2020 | -39,060.00 | -17,478.72 | -123.47% | - | - | - | ||
| Q3 2020 | -21,420.00 | -17,478.72 | -22.55% | - | - | - | ||
| Q2 2020 | -21,420.00 | -13,623.12 | -57.23% | - | - | - | ||
| Q1 2020 | -25,200.00 | -15,101.10 | -66.88% | - | - | - |
Notes
ENTERO THERAPEUTICS INC (ENTO) last reported earnings on 11/11/2025.
ENTERO THERAPEUTICS INC (ENTO) missed EPS estimates and missed revenue estimates in the most recent quarter.